Emergent BioSolutions Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Accelerated filer
State of Incorporation DE
Business Address 300 PROFESSIONAL DR, GAITHERSBURG, MD, 20879
Mailing Address 300 PROFESSIONAL DR, GAITHERSBURG, MD, 20879
Phone 240-631-3200
Fiscal Year End 1231
EIN 141902018
Financial Overview
FY2025
$1.39B
Total Assets
$906.90M
Total Liabilities
$649.30M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 3 Initial insider ownership report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | March 5, 2026 | View on SEC |
Annual Reports
10-K February 27, 2026
- Emergent BioSolutions is undergoing a profound strategic pivot, divesting non-core assets to reduce debt and focus on its core biodefense mission.
- The company maintains strong, stable relationships and multi-year contracts with the U.S. Government for key medical countermeasures, contributing over 70% of total revenue.
Insider Trading
SELL 1 insiders
2 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.